CNTX

PRE 14A - Context Therapeutics Inc. (0001842952) (Filer)

Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.

8-K - Context Therapeutics Inc. (0001842952) (Filer)

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer ("PROC") in patients that have received all standard of care therapi

S-8 - Context Therapeutics Inc. (0001842952) (Filer)

8-K - Context Therapeutics Inc. (0001842952) (Filer)

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. "We believe 2025 was a year of significant progr

10-K - Context Therapeutics Inc. (0001842952) (Filer)

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company's asset, CT-202, a Nectin-4 x CD3 TCE. Poster Presentation Details:Title:Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202Abstract Number: 5392Date and Time:Tuesday, April 21, 2026

8-K - Context Therapeutics Inc. (0001842952) (Filer)

8-K - Context Therapeutics Inc. (0001842952) (Filer)

4 - Context Therapeutics Inc. (0001842952) (Issuer)

4 - Context Therapeutics Inc. (0001842952) (Issuer)

4 - Context Therapeutics Inc. (0001842952) (Issuer)

4 - Context Therapeutics Inc. (0001842952) (Issuer)

SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in several upcoming investor conferences. Upcoming Investor Conferences Guggenheim Emerging Outlook: Biotech Summit 2026, February 11-12, 2026, New York, NYFireside Chat: Wednesday, February 11th at 8:30 AM ET1x1 Meetings on February 11th TD Cowen 46th Annual Health Care Conference, March 2-4, 2026, Boston, MAPresentation: Tuesday, March 3rd at 10:30 AM ET*1x1 Meetings on March 3rd Citizens Life Sciences Conference, March 10-11,

SCHEDULE 13G - Context Therapeutics Inc. (0001842952) (Subject)

PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context. The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted to the new employees on their hire dates (J

8-K - Context Therapeutics Inc. (0001842952) (Filer)

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology breakthroughs[1]. This momentum is already materializing, with five major oncology approvals secured in November across multiple cancer indications, demonstrating regulators' willingness to green-light promising therapies when supported by compelling clinical data[2]. Against this backdrop of regulatory evolution, several clinical-stage biotechs are advancing toward definitive registration studies and commercial readiness, po

SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today shared two posters discussing the Company's CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held November 7–9, 2025 in National Harbor, MD. CT-95 and CT-202 Highlights and Near-Term Milestones CT-95: Mesothelin x CD3 bispecific TCE CT-95 is avidity enhanced and affinity tuned to localize therapeutic activity to the tumor microenvironment.In an ongoing Phase 1 trial, Context has enrolled 6 patie